Shanghai First People's Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

  NCT07789184· Phase 3· Hua Huang, MD, PhD· Source

• Not yet recruiting

  A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo

  NCT07865312· Phase 3· Dermavon Holdings Limited· Source

• Not yet recruiting

  A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer

  NCT07928362· Ruijin Hospital· Source

• Recruiting

  Sonrotoclax Plus Azacitidine in Patients With MDS-IB2

  NCT07885397· Phase 1/2· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Not yet recruiting

  Visual Function and Exercise in Glaucoma Patients

  NCT07824232· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Not yet recruiting

  A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion

  NCT07817615· Phase 1· Changchun GeneScience Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  Luvometinib in Combination With Serplulimab for NF2-Related Tumors

  NCT07708285· Phase 1/2· Beijing Tiantan Hospital· Source

• Not yet recruiting

  Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

  NCT07713745· Phase 2· Beijing Tiantan Hospital· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

  NCT07517042· Shanghai Zhongshan Hospital· Source

• Not yet recruiting

  AI vs. Physician for Anti-VEGF Decision-Making: An RCT

  NCT07328776· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Subthalamic Nucleus-Targeted Transcranial Temporal Interference Stimulation for Motor and Non-Motor Symptoms in Parkinson's Disease

  NCT07625540· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  CGM for Insulin-Treated T2DM During Post-Discharge Transition

  NCT07414277· Shanghai 6th People's Hospital· Source

• Recruiting

  Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC

  NCT07863999· Phase 3· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Recruiting

  A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

  NCT07450599· Phase 2· Bayer· Source

• Recruiting

  Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07601737· Phase 2· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

  NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

  NCT07439120· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Not yet recruiting

  VAH vs VA in Newly Diagnosed Elderly AML

  NCT07469046· Phase 3· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Active, not recruiting

  A Study of CS060380 Tablets in Patients With MASH and Obesity

  NCT07466017· Phase 2· Cascade Pharmaceuticals, Inc· Source

• Recruiting

  Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

  NCT07548177· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy

  NCT07353398· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

  NCT07362927· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Not yet recruiting

  A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

  NCT07436221· Phase 2· Akeso· Source

• Not yet recruiting

  Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis

  NCT07328074· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Not yet recruiting

  A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.

  NCT07412236· Phase 3· Beijing Continent Pharmaceutical Co, Ltd.· Source

• Recruiting

  A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

  NCT07434518· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

  NCT07317934· Phase 3· Innostellar Biotherapeutics Co.,Ltd· Source

• Not yet recruiting

  A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

  NCT07365371· Phase 4· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure

  NCT07265349· Phase 1/2· Tasly Pharmaceutical Group Co., Ltd· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial

  NCT07272317· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

  NCT07275840· Phase 2· Innovent Biologics Technology Limited (Shanghai R&D Center)· Source

• Recruiting

  A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07244341· Phase 1· Daiichi Sankyo· Source

• Recruiting

  Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms

  NCT07272512· Phase 4· Shanghai Zhongshan Hospital· Source

• Active, not recruiting

  A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

  NCT07245407· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression

  NCT05465252· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors

  NCT07229768· Early phase 1· Yan Xing· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Not yet recruiting

  A Clinical Study on Alleviating Hemorrhoids-related Symptoms of Pelvic Radiation Therapy

  NCT07175584· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

  NCT07083154· Phase 3· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

  NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients

  NCT07142863· Phase 2· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

  NCT07038382· Phase 2· Shanghai Henlius Biotech· Source

Showing 50 of 158.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer12 recruiting
• Macular degeneration10 recruiting
• Prostate cancer9 recruiting
• Childhood cancers7 recruiting
• Lung cancer7 recruiting
• Asthma6 recruiting
• Diabetic eye disease6 recruiting
• Acute myeloid leukaemia4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Heart failure4 recruiting
• Liver and biliary tract cancer4 recruiting
• Sarcoma4 recruiting
• Type 2 diabetes4 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Bronchiectasis3 recruiting
• Hepatitis B3 recruiting
• Myelodysplastic syndromes3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Alzheimer disease2 recruiting
• Aortic stenosis2 recruiting
• Colorectal cancer2 recruiting
• COPD2 recruiting
• Coronary artery disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Head and neck cancer2 recruiting
• High blood pressure2 recruiting
• IgA nephropathy2 recruiting
• Meningioma2 recruiting
• Neuroendocrine tumours2 recruiting
• Obesity2 recruiting
• Retinitis pigmentosa2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glaucoma1 recruiting
• Liver cirrhosis1 recruiting
• Lupus (SLE)1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Terminated

  Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

  NCT06965309· Shenzhen MagicRNA Biotechnology Co., Ltd· Source

• Completed

  A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

  NCT06883695· Phase 1· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Completed

  A Trial of HRS-9813 in Healthy Subjects

  NCT06821464· Phase 1· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Completed

  Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

  NCT06492031· Vantive Health LLC· Source

• Completed

  Trial of JYB1904 in Patients With Allergic Asthma

  NCT06438757· Phase 2· Jemincare· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Completed

  A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

  NCT05901831· Phase 3· Bayer· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

  NCT06023095· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China

  NCT05958186· Lin Zhong· Source

• Completed

  Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients With Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

  NCT06744686· Phase 1· Suzhou HepaThera Biotech Co., Ltd.· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

  NCT05763823· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

  NCT05456828· Phase 1/2· Visara, Inc.· Source

• Completed

  A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

  NCT05520177· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Completed

  A Study of Multi-electrode Circular Irreversible Electroporation (IRE) Catheter and Multi-Channel IRE Generator in Paroxysmal Atrial Fibrillation (AF)

  NCT05552963· Biosense Webster, Inc.· Source

• Completed

  Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

  NCT05522231· Phase 2/3· Hutchmed· Source

• Completed

  A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

  NCT05403749· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

  NCT05277480· Phase 2· Peking University People's Hospital· Source

• Completed

  Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

  NCT05115942· Phase 3· Beijing Continent Pharmaceutical Co, Ltd.· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

  NCT04697628· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

  NCT04643470· Phase 2· BeiGene· Source

• Completed

  Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure

  NCT04468529· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Completed

  SHR0302 and Steroid As First Line Therapy for Chronic GVHD

  NCT04146207· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

  NCT04085276· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Diabetic eye disease50 works · 11 trials
• Gastric and oesophageal cancer37 works · 11 trials
• Macular degeneration30 works · 19 trials
• Glaucoma23 works · 1 trial
• Spinal cord injury17 works · 0 trials
• Retinitis pigmentosa9 works · 5 trials
• Graves' disease and hyperthyroidism5 works · 0 trials
• IgA nephropathy5 works · 3 trials